Senti Biosciences entered into an equity commitment letter with CPIF II-9 Limited, an affiliate of Celadon Partners, for the purchase of up to $4.55 million of common stock. The commitment is structured to be funded in quarterly tranches through December 31, 2027, at a price per share based on Nasdaq's Minimum Price definition. The company also agreed to provide the investor with customary demand and piggyback registration rights for the shares issued.
Senti Biosciences Holdings M&A Deal with ST NewCo Limited
Senti Biosciences announced a record date of October 30, 2026, for the distribution of contingent value rights (CVRs) related to its merger with ST NewCo Limited, which closed on October 21, 2026. Additionally, board member Edward Mathers resigned from the Board of Directors and all associated committees effective October 27, 2026.
Senti Biosciences Holdings Divestiture to ST NewCo Limited for $60M
Senti Biosciences completed the divestiture of its entire ownership interest in its operating subsidiaries, Midco and Opco, to ST NewCo Limited. In exchange, Senti shareholders will receive contingent value rights (CVRs) entitling them to up to $60.0 million in milestone payments tied to the FDA approval and commercial success of the CAR-NK cell therapy SENTI-202.